Tyler Van Buren
Stock Analyst at TD Cowen
(1.72)
# 3,249
Out of 4,944 analysts
57
Total ratings
42.22%
Success rate
-2.93%
Average return
Main Sectors:
Stocks Rated by Tyler Van Buren
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IDYA IDEAYA Biosciences | Initiates: Buy | n/a | $24.42 | - | 1 | Jul 22, 2025 | |
| CGON CG Oncology | Initiates: Buy | n/a | $26.49 | - | 1 | Jan 7, 2025 | |
| KROS Keros Therapeutics | Downgrades: Hold | n/a | $13.90 | - | 2 | Dec 12, 2024 | |
| BHVN Biohaven | Maintains: Buy | $55 → $75 | $14.39 | +421.20% | 2 | Nov 13, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Buy | n/a | $11.32 | - | 1 | Oct 8, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Buy | n/a | $15.30 | - | 1 | Sep 16, 2024 | |
| MRNA Moderna | Maintains: Hold | $70 → $60 | $26.89 | +123.13% | 6 | Sep 13, 2024 | |
| ARTV Artiva Biotherapeutics | Initiates: Buy | n/a | $2.67 | - | 1 | Aug 13, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | n/a | $11.81 | - | 1 | Aug 6, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,030 → $1,200 | $561.55 | +113.69% | 7 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $22.08 | - | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $25.76 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $85 | $120.14 | -29.25% | 5 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $57.33 | -47.67% | 2 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.46 | - | 1 | Dec 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $17.40 | - | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $70.90 | - | 1 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $37.36 | - | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $18.05 | +66.20% | 1 | May 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $50.38 | - | 1 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.13 | - | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $70 | $33.00 | +112.12% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.49 | - | 1 | Jul 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $7.09 | - | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $10.73 | - | 1 | Oct 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $1.92 | +2,504.17% | 1 | Mar 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $225 | $13.95 | +1,513.48% | 1 | Feb 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $875 | $7.65 | +11,337.91% | 1 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $10.57 | +278.43% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $30 | $12.42 | +141.55% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $0.34 | +17,599.12% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $1.60 | +3,025.00% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $1.97 | +1,422.84% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $140 → $200 | $2.66 | +7,418.80% | 1 | Jan 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $4.27 | - | 1 | Nov 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $17.21 | - | 1 | Aug 4, 2017 |
IDEAYA Biosciences
Jul 22, 2025
Initiates: Buy
Price Target: n/a
Current: $24.42
Upside: -
CG Oncology
Jan 7, 2025
Initiates: Buy
Price Target: n/a
Current: $26.49
Upside: -
Keros Therapeutics
Dec 12, 2024
Downgrades: Hold
Price Target: n/a
Current: $13.90
Upside: -
Biohaven
Nov 13, 2024
Maintains: Buy
Price Target: $55 → $75
Current: $14.39
Upside: +421.20%
Bicara Therapeutics
Oct 8, 2024
Initiates: Buy
Price Target: n/a
Current: $11.32
Upside: -
Oruka Therapeutics
Sep 16, 2024
Initiates: Buy
Price Target: n/a
Current: $15.30
Upside: -
Moderna
Sep 13, 2024
Maintains: Hold
Price Target: $70 → $60
Current: $26.89
Upside: +123.13%
Artiva Biotherapeutics
Aug 13, 2024
Initiates: Buy
Price Target: n/a
Current: $2.67
Upside: -
Cartesian Therapeutics
Aug 6, 2024
Initiates: Buy
Price Target: n/a
Current: $11.81
Upside: -
Regeneron Pharmaceuticals
Jul 23, 2024
Maintains: Buy
Price Target: $1,030 → $1,200
Current: $561.55
Upside: +113.69%
Jun 24, 2024
Initiates: Buy
Price Target: n/a
Current: $22.08
Upside: -
May 15, 2024
Initiates: Buy
Price Target: n/a
Current: $25.76
Upside: -
Apr 26, 2024
Maintains: Buy
Price Target: $90 → $85
Current: $120.14
Upside: -29.25%
Dec 11, 2023
Downgrades: Underperform
Price Target: $30
Current: $57.33
Upside: -47.67%
Dec 5, 2023
Initiates: Outperform
Price Target: n/a
Current: $4.46
Upside: -
Nov 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $17.40
Upside: -
Oct 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $70.90
Upside: -
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $37.36
Upside: -
May 22, 2023
Initiates: Outperform
Price Target: $30
Current: $18.05
Upside: +66.20%
Feb 6, 2023
Initiates: Outperform
Price Target: n/a
Current: $50.38
Upside: -
Jan 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.13
Upside: -
Aug 8, 2022
Initiates: Outperform
Price Target: $70
Current: $33.00
Upside: +112.12%
Jul 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $1.49
Upside: -
Dec 7, 2021
Initiates: Outperform
Price Target: n/a
Current: $7.09
Upside: -
Oct 11, 2021
Initiates: Outperform
Price Target: n/a
Current: $10.73
Upside: -
Mar 4, 2021
Initiates: Overweight
Price Target: $50
Current: $1.92
Upside: +2,504.17%
Feb 10, 2021
Initiates: Overweight
Price Target: $225
Current: $13.95
Upside: +1,513.48%
Nov 10, 2020
Initiates: Overweight
Price Target: $875
Current: $7.65
Upside: +11,337.91%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $10.57
Upside: +278.43%
Aug 10, 2020
Maintains: Overweight
Price Target: $35 → $30
Current: $12.42
Upside: +141.55%
Jun 29, 2020
Initiates: Overweight
Price Target: $60
Current: $0.34
Upside: +17,599.12%
Jun 29, 2020
Initiates: Overweight
Price Target: $50
Current: $1.60
Upside: +3,025.00%
Apr 22, 2020
Initiates: Overweight
Price Target: $30
Current: $1.97
Upside: +1,422.84%
Jan 13, 2020
Reiterates: Overweight
Price Target: $140 → $200
Current: $2.66
Upside: +7,418.80%
Nov 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $4.27
Upside: -
Aug 4, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $17.21
Upside: -